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Abstract
Background: Rational design of AAV capsids is a simple method for enhancing AAV transduction efficiency. AAV-DJ
is a highly recombinogenic hybrid vector created from DNA shuffling of eight AAV serotypes, which mediates efficient
gene expression both in vitro and in vivo. AAV2 and AAV8 are the closest parental vectors of AAV-DJ and it has been
reported that mutations on the 137/251/503 ubiquitination or phosphorylation sites of the AAV2 or AAV8 capsid lead
to dramatic enhancement of gene delivery. Here, we aimed to find out whether the same point mutations on the
AAV-DJ capsid could lead to significant improvement for gene delivery both in vitro and in vivo.
Results: We constructed three single point mutants (K137R/T251A/S503A) of AAV-DJ and the transduction efficiency of
these mutants and AAV-DJ were investigated using two reporter gene systems including green fluorescent protein
(GFP) and dual-luciferase (Gaussia luciferase and Firefly luciferase). Data indicated that single point mutations T251A/
S503A lead to significant improvement of dual-luciferase expression in vivo after tail vein (TV) injection in mice
respectively, despite limited enhancement of GFP expression in 293 T, Hela and HepG2 cells in vitro. Moreover, in
vivo bioluminescence image and viral genome DNA copy number in tissue analysis showed that these mutants
reserved the liver tropism characteristics, consistent with AAV-DJ.
Conclusion: Single point mutations on the 251/503 sites of AAV-DJ capsid can lead to a significant improvement for in
vivo gene expression. These enhanced AAV vectors have great potential in gene therapy applications.
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Background
Adeno-associated viruses (AAV) hold great promise in
human gene therapy and have been widely used to target
liver, muscle, heart, brain, eye, kidney and other tissues
in various studies due to its ability to provide long-term
gene expression and lack of pathogenicity [1–6]. AAVs
belong to the parvovirus family and each contains a sin-
gle strand DNA flanked by two inverted terminal repeats
[7]. There have been reported at least 12 capsid sero-
types of AAV vectors (AAV1 to AAV12) and their
unique capsid structures enable them to recognize and
transduce different cell types and organs. For instance,
AAV2-mediated RPE65 gene transfer conferred safe and
efficient improvement in retinal function in Leber’s Con-
genital Amaurosis patients by subretinal injection [8, 9].
AAV8-mediated hFIX gene transfer by a single
peripheral-vein infusion consistently leads to long-term
expression of the FIX transgene at therapeutic levels
without acute or long-lasting toxicity in patients with se-
vere hemophilia B [10].
AAV vector possesses many advantages in gene trans-
fer, but there are still some problems to be solved. AAV
infection steps include receptor binding, cell entry, intra-
cellular trafficking, uncoating, second-strand synthesis,
vector genome stabilization and so on [11]. The
ubiquitin-proteasome degradation machinery has been
considered to be a major barrier that negatively affects
AAV-mediated gene expression by degrading the viral
particles during their intracellular trafficking [12]. Point
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mutation of surface exposed tyrosine residues of AAV
capsid protein was reported as a simple and effective
method for evading phosphorylation and subsequent
ubiquitination, leading to higher transduction efficiency
both in vitro and in vivo [12, 13]. There have also been
reported that point mutations on the AAV capsid at spe-
cific tyrosine, serine, threonine and lysine residues could
lead to significant transduction improvement both in
vitro and in vivo [14–18].
AAV-DJ is a variant generated from the libraries of
AAV hybrids of eight serotypes by DNA shuffling
method [17]. It is able to efficiently transduce a broad
range of cell types in vitro but has specific liver tropism
in vivo, like AAV8. Moreover, it possesses more ability
to evade immune neutralization and thus can efficiently
deliver higher quantities of therapeutic DNA [19]. Re-
cently, AAV-DJ has been widely used for gene therapy
due to its high efficiency in gene transfer. For example,
AAV-DJ vector was used to deliver a knockout construct
to fetal pig fibroblasts with a higher targeting frequency
than the other naturally occurring serotypes [20]. AAV-
DJ mediated homologous recombination (HR) at high ef-
ficiency in human keratinocytes and had been used to
correct the LAMA3 locus in primary cells, which was
not transduced efficiently by the most commonly used
AAV serotypes [21].
To further improve the AAV-DJ vector, our study focused
on investigating whether point mutations on the capsid of
AAV-DJ can increase its transduction efficiency or broaden
the tropism both in vitro and in vivo. AAV2 and AAV8 are
the closest parental vectors of AAV-DJ and most of the
amino acid residues are similar between the capsids of
these three vectors. It has been reported that single point
mutation on the T251, T503 site of AAV2 or the K137 site
of AAV8 capsid leads to dramatic enhancement of gene de-
livery [14, 15]. In the AAV-DJ capsid, lysine (K) and threo-
nine (T) residues are retained at the 137 and 251 positions
as they are in the capsid of AAV8 or AAV2. The single
point mutation at the T503 residue, which is equivalent to
the T505 residue in the AAV-DJ capsid, has been reported
to significantly enhance AAV2-mediated gene delivery [14].
By using the online Phosphorylation and Ubiquitination
sites Prediction tools, we found out that the K137 or T251
residue but T505 residue might be an ubiquitination or
phosphorylation site, while the residue S503, which is close
to the T505 residue and equivalent to the S501 phosphoryl-
ation site of AAV2, might be an effective phosphorylation
site of AAV-DJ. Thus, we hypothesize that mutation of
these predicted sites K137, T251 and S503 in AAV-DJ may
cause similar enhancements. In this study, the single point
mutants of K137R/T251A/S503A at AAV-DJ capsid were
generated respectively and further their differences for in




Human embryonic kidney cell line HEK-293 T, human
cervical carcinoma cell line HeLa and liver hepatocellu-
lar cell line HepG2 were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). Cells
were maintained as monolayer cultures in Dulbecco’s
modified Eagle’s medium (DMEM) (Hyclone, Logan,
UT), supplemented with 10 % fetal bovine serum (FBS)
(Hyclone), 100 units/ml penicillin, 100 mg/ml strepto-
mycin (Invitrogen, Carlsbad, CA, USA) and maintain in
5 % CO2 at 37 °C.
Construction of AAV-DJ mutants
Phosphorylation and ubiquitination sites on the AAV-DJ
capsid were determined using online prediction tools
[14, 15]. The predicted sites and conservative amino acid
sequences nearby are shown in Tables 1 and 2. Muta-
tions on the AAV-DJ rep/cap plasmid were carried out
at K137R, S503A, and T251A by overlapping PCR, and
primers are shown in Table 3. A two-stage procedure
was performed to achieve the mutations. Briefly, in stage
one, two PCR extension reactions were performed in
separate tubes for each mutant. One tube contained the
forward PCR primer at 5’ site of cap and the reverse pri-
mer with point mutation, and the other contained the
reverse primer at 3’ site of cap and the forward PCR pri-
mer with the point mutation. In stage two, gel-purified
PCR products from stage one were used as template at a
ratio of 1:1, and a standard PCR was carried out using
the forward and reverse primer of cap. The presence of
the desired point mutation was verified by DNA
sequencing.
Generation of recombinant vectors
Recombinant AAV vectors were generated by polyethyle-
neimine (PEI)-based triple transfection of 293 T cells.
Briefly, twenty 150-mm2 dishes 80 % confluent with
293 T cells were transfected with AAV rep/cap, trans-
gene (pAAV-CAG-Gluc-2A-Fluc or pAAV-CBA-GFP),
and AAV-helper free (pHelper) plasmids. Cells were col-
lected at 72 h post-transfection, virus was released from
the cells by three rounds of freeze–thawing. Crude lysate
from all batches was then treated with Benzonase
(50U = ml crude lysate) for 1 h at 37 °C. Viral vector
Table 1 Analysis of the phosphorylation and ubiquitination





K137R ― Yes, high confidence
T251A Yes ―
S503A Yes ―
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stocks were purified by polyethylene glycol (PEG) pre-
cipitation followed by double CsCl gradient purifica-
tion [22]. After three changes of dialysis in virus
dialysis buffer (1 × phosphate-buffered saline [PBS],
2 % mannitol, 6 mM MgCl2) at room temperature for
6 to 8 h or at 4 °C overnight, vector genome copy
titers were determined by quantitative PCR.
Recombinant AAV vector transduction assays in vitro
To assess the efficacy of the mutant vectors we gener-
ated, 293 T, Hela and HepG2 cells were either mock in-
fected or infected with 1000 vector genomes (vg)/cell of
AAV-DJ-GFP or its K/S/T mutant vectors. At 48 h post-
transduction, GFP expression was observed and imaged
on an Olympus Model BX41 fluorescent microscope
(Olympus, Tokyo, Japan) and the GFP positive efficiency
and mean fluorescent signal intensities (MFI) were mea-
sured by flow cytometry (FACS Calibur, BD, USA).
In vivo gene transfer
Male C57BL/6 mice of 6–8 weeks were obtained and
housed in the animal center of the Academy of Military
Medicine Science. To evaluate the gene expression level
at different time points and the biodistribution of these
four vectors after tail vein injection, we used dual lucif-
erase reporter system for the in vivo study. Animals were
either mock-injected or injected with 1 × 1011 vg each of
AAV-CAG-Gluc-2A-Fluc in the same volume via the tail
vein (TV). For each group, four mice were used. All ani-
mals received humane care and the study protocol com-
plied with the institution’s ethics guidelines.
Luciferase activity assay
For gene expression level assay, blood was collected via
the tail at day 7, 14, 21, 28 and 42 post-vector adminis-
trations. The secretory Gaussia princeps luciferase
(Gluc) activity was measured using BioLux® Gaussia
Luciferase Flex Assay Kit (New England Biolabs) at dif-
ferent time point during the experiment. For each group,
the relative light unit (RLU) was determined for all the
animals at each time-point. The RLU value is related to
Gluc expression.
In vivo animal bioluminescence image analysis
After the last blood collection, mice were anaesthetized
by pentobarbital sodium (1 %, 40 mg/kg mice) via intra-
peritoneal injection. The D-luciferin substrate (Biotium,
Hayward, CA) was injected intraperitoneally at a dose of
150 μg/g. The mice were then placed in a light-tight
chamber, and images were generated using a Bioanaly-
tical Instruments (Berthold Technologies, DE). Light
was monitored in all of the experiments described at
8–12 min after the substrate injection. The visual out-
put represents the number of photons emitted/second
as a false color image where the maximum is red and
the minimum is dark blue.
Genome copy determination
After bioluminescence imaging, mice were killed and tis-
sue samples were collected from each group. Genomic
DNA was isolated using the TIANamp Genomic DNA Kit
(TIANGEN BIOTECH CO., LTD, Beijing, China) accord-
ing to the manufacturer’s protocol. Total DNA concentra-
tion was determined by spectrophotometry using
Nanodrop. Quantitative PCR was used to determine the
vector copy numbers in 100 ng of template genomic DNA
by amplifying the firefly luciferase sequence (forward
primer: ACTGCCTGCGTGAGATTCTC; reverse primer:
CAGAGTGCTTTTGGCGAAGA). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as the
housekeeping control gene. Data were captured and ana-
lyzed with ABI Prism 7500 sequence detection system ver-
sion 1.1 software (Life Technologies).
Statistical analysis
The data presented here were expressed as mean ±
standard deviation (SD) and statistical significance was
determined by the one-way ANOVA followed by
Dunnett post hoc test (compare all columns vs. con-
trol group). A p-value of < 0.05 was considered
Table 2 Conservative amino acid sequences near the three
single point mutations on AAV2, AAV8 and AAV-DJ capsids
Serotype K137R T251A S503A
AAV2 EPVKTAP ALPTYNN YSWTGAT
AAV8 EGAKTAP ALPTYNN FAWTAGT
AAV-DJ EAAKTAP ALPTYNN YSWTGAT
Table 3 Primer sequences of the three single point mutations on AAV-DJ capsid
Residue Sequence (5’ to 3’) Nucleotide change
K137R Wild-type primer sequence: TGAGGAAGCGGCTAAGACG AAG→ AGG
Mutant primer sequence: TGAGGAAGCGGCTAGGACG
T251A Wild-type primer sequence: CCCTGCCCACCTACAACAAC ACC→ GCC
Mutant primer sequence: CCCTGCCCGCCTACAACAAC
S503A Wild-type primer sequence: GTGAATACTCGTGGACTGGAG TCG→ GCG
Mutant primer sequence: GTGAATACGCGTGGACTGGAG
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statistically significant. P-values are indicated by aster-
isks (***p < 0.001, **p < 0.01, *p < 0.05).
Results
Comparison of packaging efficiencies between AAV-DJ
and its three single point mutants
To compare the packaging efficiencies between AAV-DJ
and its three single point mutants, vectors containing
double-strand GFP reporter were packaged by PEI-based
triple transfection of 293 T cells. The average titers of
the four vectors from at least two packaging experiments
were measured by quantitative PCR before vector con-
centration, which were shown in Table 4. Data indicated
that the K137R mutant had 3- to 4-fold higher pack-
aging efficiency while the other two had comparable
packaging efficiencies when compared to AAV-DJ, which
suggest that the three mutants were compatible modifi-
cations on the AAV-DJ capsid.
AAV-DJ mutants-mediated transduction in vitro
To analyze the transduction potential of the three mu-
tants of AAV-DJ, 293 T, Hela and HepG2 cells were in-
fected with 1000 vector genomes (vg)/cell. At 48 h post-
transduction, GFP expression was observed and imaged
by fluorescent microscope (Fig. 1a) and the GFP positive
efficiencies and mean fluorescent signal intensities (MFI)
were measured by flow cytometry. The K137R and
S503A point mutations led to 20–30 % enhancement
while the T251A mutation led to no significant enhance-
ment of GFP expression when compared to AAV-DJ in
these three cell lines (Fig. 1b, c and d). Similar results
were obtained when the experiment was carried out
using self-complementary GFP expressing vectors (data
not shown).
AAV-DJ mutants led to significant improvement for gene
delivery in adult C57BL/6 mice after intravenous injection
To study whether the mutants we constructed can lead
to differential gene expression in vivo, we used a dual-
luciferase reporter system: Gaussia luciferase (Gluc) and
Firefly luciferase (Fluc). The Gaussia luciferase is
secretory, providing an all-over gene expressing analysis
at different time points during the experiment, while the
Firefly luciferase is nonsecretory, allowing visualization
of localized gene expression via in vivo bioluminescence.
In this study, each animal received 1 × 1011vg vectors by
intravenous injection. First we collected venous blood
via the tail at 7, 14, 21, 28 and 42 days after vector injec-
tion and evaluated the relative light unit (RLU) emitted
by the Gaussia luciferase using a luminometer. As shown
in Fig. 2a, the RLU in each animal reached a peak at day
21 and maintained a level of 100,000 ~ 1,000,000 RLU.
By two-way ANOVA analysis, the S503A mutant displayed
significant enhancement of 2- to 3-fold at each time point
(P < 0.001), and the T251A mutant showed ~1.8-fold en-
hancement at day 21 and 28 (P < 0.01), while the K137R
mutant showed no significant enhancement. To study the
in vivo tropism of these vectors, animals were imaged after
the last blood collection and the in vivo bioluminescence
were analyzed. As shown in Fig. 2b, all vectors exhibited
liver tropism. For further evaluation, we compared the
viral genome copy numbers in different tissue samples at
42 days after vector injection by using real-time PCR
(Fig. 3). The results showed that the K137R, S503A and
T251A mutants led to significant enhancement in trans-
duction in liver samples with 2.1-, 3.5-, 2.5-fold higher
DNA copy numbers respectively, compared to AAV-DJ.
The S503A mutant resulted in 2- to 3- fold higher copy
numbers in tibialis anterior (TA) and heart tissues while
K137R showed 2.7-fold higher copy numbers in kidney
tissue. No significant differences were observed in brain,
lung and pancreas. To our surprise, the three mutants
showed a significant decrease of 2 ~ 4 fold in DNA copy
number than AAV-DJ in spleen tissue.
Discussion
Many efforts have been made to improve the efficacy of
AAV-mediated gene transfer in vitro and in vivo [23–25].
Among these, point mutation in the viral capsid protein
seems to be the most simple and universal method. AAV
transduction efficiency could be dramatically increased by
mutations of particular capsid residues, which allowed the
vectors to evade the intracellular phosphorylation and
subsequent ubiquitination and proteasome-mediated deg-
radation [26–28]. Point mutation of specific tyrosine,
serine, threonine or lysine was reported to significantly in-
crease serotype 2 and 8 AAV-mediated gene transfer both
in vitro and in vivo [14, 15, 29]. AAV-DJ, which can effi-
ciently transduce a broad range of cell types in vitro, but
has specific liver tropism in vivo, is a chimera of eight
AAV serotypes and shares >85 % sequence identity to the
parental strains [19]. Thus, we hypothesized that point
mutant of specific tyrosine, serine, threonine or lysine in
AAV-DJ can further increase its transduction efficiency or
change its tropism both in vitro and in vivo. Based on the
fact that single point mutation on the T251, T503 residues
of AAV2 or the K137 residue of AAV8 capsids can lead to
significant gene expression enhancement [14, 15], and
Table 4 The average titers of AAV-DJ and its three single point
mutant vectors for packaging double-strand and single-strand
reporter genes
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Fig. 1 Analysis of AAV-DJ and its mutant vectors transduction efficiency in vitro. 293 T, Hela and HepG2 cells were either mock infected or infected
with AAV vectors at an MOI of 1000, and 48 h later GFP expression was observed by fluorescent microscope (a) and measured by flow cytometry (b).
Quantitive analysis of the mean fluorescent signal intensities (MFI) (c) and GFP positive efficiency (d) of these cell lines were shown. Levels of signifi-
cance were determined using one-way analysis of variance. The data are shown as mean values ± SEM
DJ DJ-K137R DJ-S503A DJ-T251A
A
B
Fig. 2 AAV-DJ and its three single point mutant vectors mediated dual-luciferase expression levels in C57BL/6 mice. 1 × 1011vg of AAV vectors encoding
dual-luciferase were delivered into 6–8 weeks old C57BL/6 male mice via tail vein injection. Gaussia luciferase expression levels were detected
at 7, 14, 21, 28 and 42 days after vector injection. The values used are Relative Light Unit (RLU) emitted by the Gaussia luciferase from each animal.
Levels of significance were determined using two-way analysis of variance. The data are shown as mean values ± SEM (a). For in vivo bioluminescence
analysis, images were taken from the ventral aspect after last blood collection and the average expression rang was 100–500 photon/s (ph/s) (b)
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through online Phosphorylation and Ubiquitination sites
prediction, the K137, T251 and S503 residues of AAV-DJ
capsid may be effective ubiquitination or phosphorylation
sites, so we decided to generate the following three mu-
tants of AAV-DJ: K137R, T251A and S503A.
As shown in Results, these three mutants of AAV-DJ
showed slight enhancement of GFP gene expression in
293 T, Hela and HepG2 cells. There may be several fac-
tors that contributed to the in vitro results. As demon-
strated by Aslanidi et al., a multiple mutant of AAV2 led
to ~24-fold higher efficiency in in vitro gene transduc-
tion, which was mainly because the combined mutants
had better ability for escaping ubiquitination then result-
ing in more nuclear translocation and more transgene
expression [30]. In our study, we found no significant
difference in in vitro gene delivery between AAV-DJ and
its mutants, it might because AAV-DJ is a hybrid vector
and already has better ability to evade from phosphoryl-
ation and ubiquitination [19, 31]. Thus, single point mu-
tations of AAV-DJ may not impact viral entry and
cytoplasm/nuclear transgene distribution and is insuffi-
cient for enhancing gene delivery in vitro. It remains to
be further investigated if multiple mutants of AAV-DJ
could lead to enhancement in in vitro gene delivery.
Aside from these mutations, AAV-DJ is a hybrid vector
with receptor binding regions and major phosphoryl-
ation sites on the AAV capsid that may be different from
its parental serotypes, thus the same residue mutant
may lead to different effects [31]. Moreover, AAV-DJ dis-
play superior infectivity in many cell lines than AAV2,
which was thought to be the best ex vivo gene delivery
AAV vector, so there may be no significant potential for
AAV-DJ mediated up-regulation of gene expression in
vitro [19, 31]. However, significant enhancements in sys-
temic gene expression level or liver tropism were ob-
served in vivo when the vectors containing the luciferase
reporters were injected into mice via tail vein. Two mu-
tants we constructed showed significant enhancement in
transduction efficiency in liver, especially for the S503A
which exhibited rapid gene expression and maintained
higher gene expression level at all the time points inves-
tigated. Since the S503 residue of AAV-DJ was equiva-
lent to the S501 residue of AAV2, which turn out to be
an effective phosphorylation site of AAV2, it remains to
be further studied if the S501A mutant of AAV2 could
lead to significant enhancement in AAV2-mediated gene
delivery. We would not expect a huge increase for gene
expression just as the same mutants of AAV2 did, since
AAV-DJ is a hybrid vector and had been strictly selected
with human antisera, and has the best ability to avoid
phosphorylation in vivo [19, 31].
Recently, some conflicting results were reported on
the same residue mutants of different AAV serotypes.
For example, the Y to F mutants of AAV2 can dramatic-
ally enhance gene transfer and expression both in vitro
and in vivo [12, 13, 32]. However, Qiao and co-workers
found negative effects when Y to F mutants were applied
to AAV8 and AAV9 [33]. Our study on Y to F mutants
of both AAV8 and AAV-DJ also displayed minimal en-
hancement of gene expression in vivo (to be published).
Fig. 3 Viral genome DNA copy number analysis in selected tissues. After bioluminescence imaging, animals were killed, genomic DNA was
isolated from different tissues, and 100 ng DNA of each tissue sample was used to determine viral genome DNA copy numbers by using primers
of Firefly luciferase. Levels of significance were determined using one-way analysis of variance. The data are shown as mean values ± SEM
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Furthermore, Qiao et al. also obtained negative results of
K137R on AAV8 [34], which were reported to enhance
gene expression by 5 to 10 fold in liver [15]. These in-
consistent results may be caused by using different re-
porters contributing to various measurements of
transduction efficiency, incorrect vector titers, dilutions,
and/or inconsistent vector potency from batch to batch.
In summary, the AAV-DJ capsid mutants (S503A/
T251A) generated in this study led to significant im-
provements in systemic transgene expression and exhib-
ited liver tropism after tail vein injection in mice. Thus,
the enhanced AAV vectors have great potential for fu-
ture gene therapy applications.
Conclusions
We successfully constructed three mutants based on
phosphorylation or ubiquitination sites on the AAV-DJ
capsid. Our results show that the point mutants S503A/
T251A can lead to improvement in gene delivery and
minimal change in tissue tropism. These enhanced AAV
vectors have great potential for future gene therapy
applications.
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